Screener
Ardelyx ARDX Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ardelyx in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Ardelyx’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437402-26-000044
| (in thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other cost of revenue(3) | 2,070 | 9,158 | 4,006 | 19,121 |
| Research and development(4) | 23,195 | 13,251 | 40,781 | 24,586 |
| Selling(4) | 66,949 | 57,952 | 134,344 | 114,752 |
| General and administrative(4) | 22,083 | 16,764 | 45,399 | 34,701 |
| Stock-based compensation | 15,316 | 11,687 | 29,474 | 23,775 |
| Loss from operations | (12,425) | (14,395) | (45,218) | (50,744) |
| Other reconciliation items(5) | (4,296) | (4,684) | (9,108) | (9,479) |
| Net loss | $(16,721) | $(19,079) | $(54,326) | $(60,223) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ardelyx's business segments — stock-based comp?
- Ardelyx (ARDX) reported business segments — stock-based comp of $15.32M in Q2 2026.
- How has Ardelyx's business segments — stock-based comp changed year-over-year?
- Ardelyx's business segments — stock-based comp increased by 31.1% year-over-year, from $11.69M to $15.32M.
- What is the long-term trend for Ardelyx's business segments — stock-based comp?
- Over 3 years (2022 to 2025), Ardelyx's business segments — stock-based comp has grown at a 24.9% compound annual growth rate (CAGR), from $25.14M to $48.96M.
- What does business segments — stock-based comp mean?
- Represents the non-cash expense associated with equity-based awards granted to employees and executives as part of their total compensation. This metric reflects the cost of talent retention and alignment of interests between staff and shareholders. It is a significant component of operating expenses for growth-stage biotechnology firms.
Ask your AI about Ardelyx's business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude